GO
Loading...

Biogen Idec Inc

More

  • If you could be any other CEO, who would you be? Friday, 16 Jan 2015 | 12:14 PM ET
    Tesla Motors CEO Elon Musk speaking in Detroit, January 13, 2015.

    At the J.P. Morgan Healthcare Conference, executives name the CEOs they'd most like to replace.

  • Early Glance: Biotechnology companies Friday, 16 Jan 2015 | 10:13 AM ET

    Amgen Inc. rose $1.19 or. 8 percent, to $153.11. Biogen Idec rose $2.82 or. 8 percent, to $342.70. Celgene Corp. rose $1.77 or 1.5 percent, to $120.04.

  • Final Glance: Biotechnology companies Thursday, 15 Jan 2015 | 6:08 PM ET

    Amgen Inc. fell $3.24 or 2.1 percent, to $151.92. Biogen Idec fell $8.87 or 2.5 percent, to $339.88. Celgene Corp. fell $2.83 or 2.3 percent, to $118.27.

  • SAN FRANCISCO/ WASHINGTON Jan 15- U.S. healthcare executives say Obamacare is likely here to stay, despite repeated calls from Republican lawmakers for repeal of the 2010 law aimed at providing health coverage for millions of uninsured Americans. Top executives who gathered in San Francisco this week for the annual J.P. Morgan Healthcare conference, say that...

  • Midday Glance: Biotechnology companies Thursday, 15 Jan 2015 | 1:59 PM ET

    Amgen Inc. fell $2.75 or 1.8 percent, to $152.41. Biogen Idec fell $4.64 or 1.3 percent, to $344.11. Celgene Corp. fell $3.28 or 2.7 percent, to $117.82.

  • Early Glance: Biotechnology companies Thursday, 15 Jan 2015 | 11:00 AM ET

    Amgen Inc. fell $1.45 or. 9 percent, to $153.71. Biogen Idec fell $4.30 or 1.2 percent, to $344.45. Celgene Corp. fell $1.82 or 1.5 percent, to $119.28.

  • Healthcare Executives on a Saturday  Thursday, 15 Jan 2015 | 10:30 AM ET

    Healthcare executives talk about their weekend activities.

  • Biogen exec says he would trade places with Musk  Thursday, 15 Jan 2015 | 8:15 AM ET

    Healthcare industry executives name the CEOs they'd be most willing to trade places with.

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....

  • Biogen Idec beefs up pain pipeline  Monday, 12 Jan 2015 | 3:16 PM ET

    Dr. George Scangos, Biogen Idec CEO, discusses new therapies in multiple sclerosis, Alzheimer's disease and pain.

  • Big deals, data kick off JPMorgan health conference Monday, 12 Jan 2015 | 1:04 AM ET

    The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.

  • Biogen's anti-LINGO shows mixed results in study Thursday, 8 Jan 2015 | 12:44 PM ET

    Biogen Idec's anti-LINGO-1, showed promise in a mid-stage study in reversing the nerve damage associated with acute optic neuritis.

  • *Family Dollar slips after earnings. *Brent crude holds above $51 a barrel. "Jobless claims they were about in line, maybe a little weaker than expected but the jobs market still points to jobs growth," said Peter Cardillo, chief market economist at Rockwell Global Capital in New York.

  • *Family Dollar falls after earnings. *Brent crude holds above $51 a barrel. "Jobless claims they were about in line, maybe a little weaker than expected but the jobs market still points to jobs growth," said Peter Cardillo, chief market economist at Rockwell Global Capital in New York.

  • *Family Dollar falls in premarket after earnings. *Brent crude holds above $51 a barrel. NEW YORK, Jan 8- U.S. stock index futures rose on Thursday, putting equities on track for a second day of gains after the S&P 500 snapped a five-day losing skid and ahead of data on the labor market.

  • Biogen shares pop on phase II data  Thursday, 8 Jan 2015 | 7:54 AM ET

    Biogen is reporting positive results in its optic drug trial, reports CNBC's Meg Tirrell.

  • New Biogen drug may help reverse eye scarring Thursday, 8 Jan 2015 | 7:34 AM ET

    Biogen's anti-LINGO-1 showed potential in a phase 2 trial to reverse the nerve damage in an eye disorder called acute optic neuritis.

  • After-hours buzz: WD-40, Brocade, Zumiez & more Wednesday, 7 Jan 2015 | 5:19 PM ET

    Check out which companies are making headlines after the bell Wednesday: WD-40, Brocade, Zumiez, GM & more.

  • Cramer's 10 lessons learned from 2014 Monday, 5 Jan 2015 | 6:10 PM ET
    Traders on the floor of the New York Stock Exchange.

    On a down day in the market, Jim Cramer thinks this is the perfect time to review the silly preconceptions of 2014.

  • Midday movers: Exxon Mobil, Chevron, Hess & more Monday, 5 Jan 2015 | 12:56 PM ET

    Some of Monday's midday movers: